| Literature DB >> 27693125 |
Evangelia Papadimitriou1, Evangelia Pantazaka2, Penelope Castana2, Thomas Tsalios2, Alexandros Polyzos3, Dimitris Beis3.
Abstract
Pleiotrophin (PTN) is a secreted heparin-binding growth factor that through its receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) has a significant regulatory effect on angiogenesis and cancer. PTN and RPTPβ/ζ are over-expressed in several types of human cancers and regulate important cancer cell functions in vitro and cancer growth in vivo. This review begins with a brief introduction of PTN and the regulation of its expression. PTN receptors are described with special emphasis on RPTPβ/ζ, which also interacts with and/or affects the function of other important targets for cancer therapy, such as vascular endothelial growth factor A, ανβ3 and cell surface nucleolin. PTN biological activities related to angiogenesis and cancer are extensively discussed. Finally, up to date approaches of targeting PTN or RPTPβ/ζ for cancer treatment are presented. Insights into the regulatory role of PTN/RPTPβ/ζ on angiogenesis will be extremely beneficial for future development of alternative anti-angiogenic approaches in cancer therapy. Copyright ÂEntities:
Keywords: Angiogenesis; Cancer; Drug target; Pleiotrophin; Receptor protein tyrosine phosphatase zeta; Therapy
Mesh:
Substances:
Year: 2016 PMID: 27693125 DOI: 10.1016/j.bbcan.2016.09.007
Source DB: PubMed Journal: Biochim Biophys Acta ISSN: 0006-3002